Insulin lispro versus regular insulin in children with type 1 diabetes on twice daily insulin

Abstract

The main advantage of insulin lispro in children on twice daily insulin was found to be its greater convenience, this being achieved without a deterioration in glycaemic control. The higher 3 am blood glucose levels in those on insulin lispro could translate to reduced nocturnal hypoglycaemia in some individuals.

Comparable Efficacy and Safety of Insulin Glulisine and Insulin Lispro When Given as Part of a Basal–Bolus Insulin Regimen in a 26-Week Trial in Pediatric Patients with Type 1 Diabetes

“…This is not entirely unexpected, as comparable trials in children and adolescents show similar increases as a result of lispro treatment, and the results of the present study are consistent with these trials. 8,[22][23][24] These findings are suggestive of the importance of factors other than insulin, such as patient attitude and lifestyle, in achieving and maintaining good glycemic control.…”

Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis

“…The number of patients in each study ranged from 7 to 1008. Of the 48 crossover studies, 19,20,24,25,30,32,33,35,[37][38][39][42][43][44][45]47,48,51,55,56,58,[62][63][64][65][66][67][69][70][71][72][73][74]78,79,[81][82][83]85,87,89,93,96,[100][101][102]121 most lacked or did not mention a washout period. All studies were of open-label design.…”

“…For rapid-acting insulin analogues, we identified 765 citations, of which we reviewed 26 and selected 5 trials [19][20][21][22][23] for inclusion in our analysis. We thus had a total of 68 randomized controlled trials for the current meta-analysis, including 63 trials from the original health technology assessment 13 ( Figure 1).…”

Contemporary Australian outcomes in childhood and adolescent type 1 diabetes: 10 years post the Diabetes Control and Complications Trial

“…Fairchild et al in a NSW study reported that children using insulin lispro in a twice-daily insulin injection regimen had a significantly higher 3.00 hours BGL than those receiving regular insulin, suggesting a lower risk of nocturnal hypoglycaemia with the newer insulin analogue, consistent with data from overseas. 36 Data from WA showed a decrease in episodes of severe hypoglycaemia from 32.9 to 11.4 per 100 patient years in patients going onto pump therapy after a mean follow-up duration of 1.4 years. 22 Local data are not yet available on rates of hypoglycaemia in patients on insulin glargine or detemir-containing regimens.…”